Lexeo Therapeutics (LXEO) Stock Overview
A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
LXEO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lexeo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.61 |
| 52 Week High | US$10.99 |
| 52 Week Low | US$1.45 |
| Beta | 1.78 |
| 1 Month Change | 5.72% |
| 3 Month Change | 45.17% |
| 1 Year Change | 31.82% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.38% |
Recent News & Updates
Lexeo Therapeutics: Behind The Rebound
Nov 06Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?
Sep 25
Recent updates
Lexeo Therapeutics: Behind The Rebound
Nov 06Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?
Sep 25Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Deliver On Growth Plans?
Jan 20We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29Shareholder Returns
| LXEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | -2.0% | -1.1% |
| 1Y | 31.8% | 22.9% | 14.7% |
Return vs Industry: LXEO exceeded the US Biotechs industry which returned 23% over the past year.
Return vs Market: LXEO exceeded the US Market which returned 14.6% over the past year.
Price Volatility
| LXEO volatility | |
|---|---|
| LXEO Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LXEO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LXEO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 61 | R. Townsend | www.lexeotx.com |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.
Lexeo Therapeutics, Inc. Fundamentals Summary
| LXEO fundamental statistics | |
|---|---|
| Market cap | US$701.04m |
| Earnings (TTM) | -US$104.97m |
| Revenue (TTM) | n/a |
Is LXEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LXEO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$65.95m |
| Gross Profit | -US$65.95m |
| Other Expenses | US$39.01m |
| Earnings | -US$104.97m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LXEO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/03 04:55 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexeo Therapeutics, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |